Table 1 Baseline characteristics in 136 included patients with rheumatoid arthritis (RA) and the 102 non-participants (mean (SD) values for continuous variables (also median and range for vdH Sharp score and DXR-BMD), percentages for counts)
Patients included in study (n = 136)Patients not included in study (n = 102)*
Age (years)51.3 (12.1)52.8 (14.2)
Positive anti-CCP6259
Positive IgM RF4848
Disease duration (years)2.2 (1.2)2.4 (1.1)
CRP (mg/litre)9.4 (12.2)11.0 (13.4)
ESR (mm/h)26.2 (20.9)25.5 (18.3)
HAQ score (scale 0–3)0.9 (0.6)1.0 (0.7)
Current users of corticosteroids2629
Current users of DMARDs5449
vdH Sharp score6.8 (12.2)NA
2.0 (0–69.0)
Hand DXR-BMD (g/cm2)0.55 (0.09)NA
0.55 (0.33–0.77)
  • *All group comparisons p>0.05.

  • CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; DXR-BMD, digital x ray radiogrammetry bone mineral density; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NA, not available; RF, rheumatoid factor; vdH Sharp, van der Heijde modification of the Sharp score.